Sulfuric acid mono-((3S,8R,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl) ester | 61066-66-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Sulfuric acid mono-((3S,8R,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl) ester
• 英文别名: [(3S,8R,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] hydrogen sulfate
• CAS: 61066-66-8
• 化学式: C₁₉H₃₀O₅S
• 分子量: 370.51
• InChiKey: RKMXJTARZZQEOO-LOVVWNRFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  92.2
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• REMEDY FOR HORMONE-DEPENDENT CANCER
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1568381A1

  公开（公告）日：2005-08-31

  A therapeutic agent for a hormone-dependent cancer, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, which may be administered together or separately at an interval, is provided. A method for treating a hormone-dependent cancer, which comprises administering (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy together or separately at an interval, is also provided. A steroid-sulfatase inhibitor which is used in combination with an agent for hormone therapy and/or an agent for chemotherapy, and which is administered together therewith or separately therefrom at an interval, is also provided. A kit for treating a hormone-dependent cancer, which comprises a first component comprising (a) a steroid-sulfatase inhibitor and a second component comprising (b) an agent for hormone therapy and/or an agent for chemotherapy, is also provided. A pharmaceutical composition, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, is also provided. Further, use of (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy for the manufacture of a therapeutic agent for a hormone-dependent cancer is provided.

  本发明提供了一种激素依赖性癌症的治疗剂，它包括(a)类固醇硫酸酯酶抑制剂和(b)激素治疗剂和/或化疗剂，这两种药物可以一起给药，也可以间隔一段时间分别给药。还提供了一种治疗激素依赖性癌症的方法，该方法包括(a)类固醇-硫酸酯酶抑制剂和(b)激素治疗制剂和/或化疗制剂，它们可以一起给药，也可以间隔一段时间分别给药。还提供了一种类固醇硫酸酯酶抑制剂，该抑制剂与激素治疗剂和/或化疗剂联合使用，并在一定间隔时间内一起或分开给药。还提供了一种用于治疗激素依赖性癌症的试剂盒，它包括由(a)类固醇硫酸酯酶抑制剂组成的第一组分和由(b)激素治疗剂和/或化疗剂组成的第二组分。还提供了一种药物组合物，它包含(a)类固醇硫酸酯酶抑制剂和(b)激素治疗剂和/或化疗剂。此外，还提供了使用(a)类固醇硫酸酯酶抑制剂和(b)激素治疗剂和/或化疗剂制造激素依赖性癌症治疗剂的方法。
• Therapeutic treatment methods 2
  申请人：Reading L. Christopher

  公开号：US20050101581A1

  公开（公告）日：2005-05-12

  The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.

  本发明涉及使用化合物来改善或治疗诸如囊性纤维化、中性粒细胞减少症或其他示例性疾病。可使用的示例化合物包括 3β-羟基-17β-氨基雄甾-5-烯、3β-羟基-16α-氟-17β-氨基雄甾-5-烯、3α-羟基-16α-氟-17β-氨基雄甾-5-烯、3β-羟基-16β-氟-17β-氨基雄甾-5-烯、1α,3β-二羟基-4α-氟-雄甾-5-烯-17-酮、1α,3β,17β-三羟基-4α-氟雄甾烷-5-烯、1β,3β-二羟基-6α-溴雄甾烷-5-烯、1α-氟-3β,12α-二羟基雄甾烷-5-烯-17-酮、1α-氟-3β,4α-二羟基雄甾烷-5-烯和 4α-氟-3β,6α,17β-三羟基雄甾烷。
• Porcine sulfotransferase 2A1 polynucleotide sequence, protein, and methods of use for same
  申请人：Squires James E.

  公开号：US20060024708A1

  公开（公告）日：2006-02-02

  The invention pertains to the identification and isolation of a gene involved in the boar taint phenotype. A porcine form of a gene, designated SULT2A1, is identified. The invention additionally provides methods of inhibiting or reducing boar taint using the novel SULT2A1 gene or gene product. Methods for reducing or inhibiting boar taint and methods for screening compounds to modulate SULT2A1 are also disclosed.

  本发明涉及鉴定和分离一种与公猪污点表型有关的基因。本发明鉴定了一种猪形式的基因，命名为 SULT2A1。本发明还提供了利用新型 SULT2A1 基因或基因产物抑制或减少公猪疫病的方法。本发明还公开了减少或抑制猪瘟的方法以及筛选调节 SULT2A1 的化合物的方法。
• PORCINE SULFOTRANSFERASE 2A1 POLYNUCLEOTIDE SEQUENCE, PROTEIN, AND METHODS OF USE FOR SAME
  申请人：UNIVERSITY OF GUELPH

  公开号：EP1766025A1

  公开（公告）日：2007-03-28
• EP1766025A4
  申请人：——

  公开号：EP1766025A4

  公开（公告）日：2008-05-14